ASAM submitted a letter of support for the proposal by the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention to add ICD-10-CM codes for synthetic cannabinoid use and poisoning.

ASAM's letter focuses on federal policy efforts needed to further strengthen safety and care quality for patients with addiction in health systems that provide care to rural and underserved populations.

Legislation to Expand the Addiction Treatment Workforce Would Create 1,000 Additional Residency Positions Over Five-Year Period

Resolution Recognizes Addiction as a Complex Medical Disease, Urges Support for Evidence-Based Treatment, and Supports Efforts to Prevent and Destigmatize Substance Use Disorder and Addiction

ASAM sent a letter to Walmart's Health and Wellness Compliance Practice requesting more information on their decision-making criteria.

ASAM, along with other leading addiction prevention, treatment, and recovery stakeholder groups endorse the Medication Access and Training Expansion (MATE) Act.

ASAM responded to an RFI regarding challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment.

ASAM submitted its comments on SAMHSA's NPRM Regarding Confidentiality of Substance Use Disorder Patient Records, which would make significant regulatory changes to 42 CFR Part 2